Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation in leukemia. Current status.

G W Santos

    Cancer
    |December 1, 1984
    PubMed
    Summary

    Bone marrow transplantation (BMT) offers a curative option for hematopoietic malignancies by rescuing patients from toxic cytoreductive therapy. Different BMT types, including allogeneic, syngeneic, and autologous, show promise for long remissions and cures.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment.

    Journal of hematotherapy·1998
    Same author

    Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective.

    Annals of the New York Academy of Sciences·1995
    Same author

    Bone marrow transplantation.

    Current opinion in oncology·1995
    Same author

    Lichenoid graft-vs-host disease in an autologous bone marrow transplant recipient.

    Archives of dermatology·1995
    Same author

    The role of autologous hematopoietic stem cell transplantation in hematologic malignancy.

    Current opinion in oncology·1994
    Same author

    The eye in bone marrow transplantation. VI. Retinal complications.

    Archives of ophthalmology (Chicago, Ill. : 1960)·1994

    Area of Science:

    • Hematology
    • Oncology
    • Immunology

    Background:

    • Intensive cytoreductive therapy can cure hematopoietic malignancies but causes lethal marrow toxicity.
    • Bone marrow transplantation (BMT) is a rescue strategy for this toxicity.
    • BMT donors can be HLA-matched siblings (allogeneic), identical twins (syngeneic), or the patient (autologous).

    Purpose of the Study:

    • To review the efficacy and challenges of different bone marrow transplantation approaches in treating hematopoietic malignancies.
    • To highlight factors influencing successful outcomes in BMT.
    • To discuss ongoing research addressing BMT-related complications.

    Main Methods:

    • Review of existing literature on intensive cytoreductive therapy and BMT for various hematologic cancers.
    • Analysis of outcomes based on BMT type (allogeneic, syngeneic, autologous) and patient-specific factors.
    • Discussion of current research on mitigating BMT complications like graft-versus-host disease and infections.

    Main Results:

    • Allogeneic BMT achieves 50-60% long-term remission and cure rates in acute leukemia, CML, and non-Hodgkin's lymphoma.
    • Optimal results are observed in younger patients and those transplanted early in their disease course.
    • Syngeneic BMT leads to significant cures but has higher relapse rates.
    • Autologous BMT shows promise, with ongoing research into purging residual tumor cells.

    Conclusions:

    • Bone marrow transplantation is a vital therapeutic option for hematopoietic malignancies, offering potential cures.
    • Allogeneic, syngeneic, and autologous BMT each have distinct advantages and challenges.
    • Continued research into graft-versus-host disease, infections, and marrow purging is crucial for advancing BMT efficacy.

    Related Experiment Videos